AbbVie (NASDAQ:ABBV) is in the midst of a transition. AbbVie began life about a decade ago when it was spun off from health care and medical devices company Abbott (NYSE:ABT). Now, however, AbbVie must adapt quickly or ABBV stock will be in big trouble. Up until recently, AbbVie relied on its blockbuster Humira drug for around 60% of its revenue. However, it could lose most of those sales over the next few years, as Humira’s patent protection will disappear in 2023.
AbbVie simply can’t be judged based on its 2019 earnings and dividend. The real question is what its results will look like in 2023 and 2024 as its revenue starts to plunge during the beginning of the post-Humira era. I’ve seen little evidence indicating that it will be able to replace its current profits after the patent cliff arrives. The Allergan deal looks like a risky and potentially even desperate measure. For a company with debt and declining revenues, an easy fix is reducing the dividend.
Source: InvestorPlace
Related Articles:
- Why We Are Dividend Growth Investors
- 3 Higher Yielding, Lower Risk Stocks To Perk Up Your Dividend Income
- Don't Touch These 3 Dividend Stocks!
- 4 Higher Yielders With A Low Free Cash Flow Payout
- 2 Dividend Stocks Headed In The Right Direction
AbbVie Will Be in Big Trouble When Its Patent Cliff Arrives
Posted by D4L | Friday, June 19, 2020 | 0 comments »________________________________________________________________
Subscribe to:
Post Comments (Atom)
~
Popular Posts Last 30 Days
-
In an attempt to put a lid on inflation, the Federal Reserve has stated that it intends to raise its benchmark federal-funds rate by 0.25% a...
-
If you have contemplated selling shares of some of the companies you own this year, you likely aren't alone. Considering how volatile th...
-
Readers may want to do a stock valuation on the stocks in their favorite sectors and wait patiently until they become cheap. Patience is a v...
-
Dividend growth stocks are among our favorite investment groups because you get so much bang for your buck. Not only do the companies pay di...
-
Dividend utility stocks might seem bad for your portfolio during high inflation and rising interest rates. However, the sector has done well...
-
Companies that have either been through past downturns or have the pricing power to offset the costs of inflation provide a crucial element ...
-
Dividend reinvestment plans, or DRIPs, can be effective ways to accumulate shares of high-quality companies for those with limited capital t...
-
We picked up two investments that carry excellent yields combined with some healthy upside in the share price. We also dropped one of our po...
-
If you're wishing you had a little more exposure to income investments right now and a little less exposure to growth, you're not al...
-
Do you have the stomach for contrarian investing - betting against the crowd? Sometimes that's necessary in order to find value. Why buy...
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.